Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 11,200 KRW
Change Today -350.00 / -3.03%
Volume 206.8K
115450 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 2:10 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

g-treebnt co ltd (115450) Snapshot

Open
11,750
Previous Close
11,550
Day High
11,950
Day Low
11,200
52 Week High
07/17/15 - 19,800
52 Week Low
01/16/15 - 2,700
Market Cap
227.2B
Average Volume 10 Days
284.3K
EPS TTM
-76.18
Shares Outstanding
20.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for G-TREEBNT CO LTD (115450)

Related News

No related news articles were found.

g-treebnt co ltd (115450) Related Businessweek News

No Related Businessweek News Found

g-treebnt co ltd (115450) Details

G-treeBNT Co., Ltd. researches and develops multimedia software in South Korea and internationally. The company offers FXUI, a middleware for embedded 2D GUI, which supports diverse hardware and software environment; FXUI-3D, an embedded GUI middleware solution for emerging 3D graphics; and FXUI-S3D, a solution to support stereoscopic 3D (S3D) screen display, and framework for S3D contents production and display. It also provides FX-Studio, an integrated solution for use in content development with embedded devices. In addition, the company produces pumps, motors, and other components; and focuses on drama production. Further, it develops pharmaceutical products. The company was formerly known as Digital Aria, Co., Ltd. and changed its name to G-treeBNT Co., Ltd. in 2014. G-treeBNT Co., Ltd. was founded in 2000 and is based in Seongnam, South Korea.

Founded in 2000

g-treebnt co ltd (115450) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

g-treebnt co ltd (115450) Key Developments

G-treeBNT Co., Ltd. Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome

RegeneRx Biopharmaceuticals Inc. was informed by its licensee, GtreeBNT Co. Ltd. headquartered in Gyeonggi-do, South Korea, that it has received approval from the Ministry of Food and Drug Safety (MFDS) in Korea to conduct a Phase 2b/3 clinical trial in patients with dry eye syndrome (DES). The Phase 2b/3 clinical trial will be a multicenter, randomized, double-masked study that will be conducted in approximately 360 patients with DES. The trial will evaluate the efficacy and superiority of GBT-201 compared to placebo. GBT-201/RGN-259 is a sterile, preservative-free eye drop designed to treat eye disorders such as DES and neurotrophic keratopathy (NK), among others. It is the first pharmaceutical company in Korea to reach Phase 3 clinical trial status for a new drug for the treatment of DES.

G-treeBNT Co., Ltd., Annual General Meeting, Mar 31, 2015

G-treeBNT Co., Ltd., Annual General Meeting, Mar 31, 2015., at 09:00 Korea Standard Time.

Regenerx Biopharmaceuticals and G-treeBNT Co., Ltd. Partner to Develop RGN-259 in the US for Ophthalmic Indications

RegeneRx Biopharmaceuticals reported the launch of an agreement to develop RGN-259 for dry eye syndrome and neurotrophic keratitis (an orphan indication) in the US in partnership with G-treeBNT Co. This joint venture (JV) agreement allows G-treeBNT to conduct and fund all clinical trials and product development through approval of a new drug application (NDA). Under the license agreement, RegeneRx granted the JV an exclusive, royalty-bearing license to market and sell it's RGN-259 in the US as well as contributed all of its non-clinical and clinical data generated to date. G-treeBNT will hold a majority equity stake in the JV that will increase as it successfully reaches development milestones. In addition, RegeneRx has the right to approve key product licensing, mergers or acquisitions; receive a total of USD 1 million in two tranches, as well as royalties ranging from high single digits to low double digits, depending on medical indications approved and if the JV's ophthalmic product candidates are commercialised internally or through a third party; retain a significant equity position in the JV; and will not be required to provide any funding for the venture.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
115450:KS 11,200.00 KRW -350.00

115450 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 115450.
View Industry Companies
 

Industry Analysis

115450

Industry Average

Valuation 115450 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.6x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact G-TREEBNT CO LTD, please visit www.digitalaria.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.